Gene Expression Profiles in Cervical Cancer with Radiation Therapy Alone and Chemo-radiation Therapy

자궁경부암의 방사선치료 및 방사선항암화학 병용치료에 따른 유전자발현 조절양상

  • Lee Kyu Chan (Department of Radiation Oncology Kachon Medical School) ;
  • Kim Meyoung-kon (Departments of Biochemistry College of Medicine, Korea University) ;
  • Kim Jooyoung (Department of Radiation Oncology Kachon Medical School) ;
  • Hwang You Jin (Laboratory of Molecular Biology, Kachon Medical School,) ;
  • Choi Myung Sun (Radiation Oncology, College of Medicine, Korea University) ;
  • Kim Chul Yong (Radiation Oncology, College of Medicine, Korea University)
  • 이규찬 (가천의과대학교 방사선종양학과) ;
  • 김명곤 (고려대학교 의과대학 생화학교실) ;
  • 김주영 (가천의과대학교 방사선종양학과) ;
  • 황유진 (가천의과대학교 분자생물학연구실) ;
  • 최명선 (고려대학교 방사선종양학교실) ;
  • 김철용 (고려대학교 방사선종양학교실)
  • Published : 2003.03.01


Purpose : To analyze the gene expression Profiles of uterine ceulcal cancer, and its variation after radiation therapy, with or without concurrent chemotherapy, using a CDNA microarray. Materials and Methods :Sixteen patients, 8 with squamous ceil carcinomas of the uterine cervix, who were treated with radiation alone, and the other 8 treated w14h concurrent chemo-radiation, were Included in the study. Before the starling of the treatment, tumor biopsies were carried out, and the second time biopsies were peformed after a radiation dose of 16.2$\~$27 Gy. Three normal cervix tissues were used as a control group. The microarray experiments were peformed with 5 groups of the total RNAs extracted individually and then admixed as control, pre-radiation therapy alone, during-radiation therapy alone, pre-chemoradiation therapy, and during-chemoradlation therapy. The 33P-iabeled CDNAS were synthesized from the total RNAs of each group, by reverse transcription, and then they were hybridized to the CDNA microarray membrane. The gene expression of each microarrays was captured by the intensity of each spot produced by the radioactive isotopes. The pixels per spot were counted with an Arrayguage, and were exported to Microsoft Excel The data were normalized by the Z transformation, and the comparisons were peformed on the Z-ratio values calculated. Results : The expressions of 15 genes, including integrin linked kinase (ILK), CDC28 protein kinase 2, Spry 2, and ERK 3, were increased with the Z-ratio values of over 2.0 for the cervix cancer tissues compared to those for the normal controls. Those genes were involved In cell growth and proliferation, cell cycle control, or signal transduction. The expressions of the other 6 genes, Including G protein coupled receptor kinase 5, were decreased with the Z-ratio values of below -2.0. After the radiation thorapy, most of the genes, with a previously Increase expressions, represented the decreased expression profiles, and the genes, with the Z-ratio values of over 2.0, were cyclic nucleotlde gated channel and 3 Expressed sequence tags (EST). In the concurrent chemo-radiation group, the genes involved in cell growth and proliferation, cell cycle control, and signal transduction were shown to have increased expressions compared to the radiation therapy alone group. The expressions of genes involved in anglogenesis (angiopoietln-2), immune reactions (formyl peptide receptor-iike 1), and DNA repair (CAMP phosphodiesterase) were increased, however, the expression of gene involved In apoptosls (death associated protein kinase) was decreased. Conclusion : The different kinds of genes involved in the development and progression of cervical cancer were identified with the CDNA microarray, and the proposed theory is that the proliferation signal stalls with ILK, and is amplified with Spry 2 and MAPK signaling, and the cellular mitoses are Increased with the increased expression oi Cdc 2 and cell division kinases. After the radiation therapy, the expression profiles demonstrated 4he evidence of the decreased cancer cell proliferation. There was no sigificant difference in the morphological findings of cell death between the radiation therapy aione and the chemo-radiation groups In the second time biopsy specimen, however, the gene expression profiles were markedly different, and the mechanism at the molecular level needs further study.


  1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841<827::AID-IJC6>3.0.CO;2-P
  2. Central Cancer Registry Center in Korea. Ministry of Health and Welfare, Republic of Korea. Annual report of the central cancer registry in Korea (1999. 1. -1999. 12.) April, 2001
  3. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143
  4. Kang OC, Choi EK, Chung WK, et al. Concurrent chemoraiotherapy in locally advanced carcinoma of the uterine cervix. J Korean Soc Ther Radiol 1998;16:311-323
  5. SChena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-470
  6. Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101-108
  7. Bertucci F, Houlgatte R, Benziane A, et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000;9:2981-2991
  8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511
  9. Park GH, Choe J, Choo HJ, Park YG, Sohn J, Kim MK. Genome-wide expression profiling of 8-chloroadenosine- and 8-chloro-cAMP-treated human neuroblastoma cells using radioactive human cDNA microarray. Exp Mol Med 2002;34(3):184-193
  10. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95(25):14863-14868
  11. Villaret DB, Wang T, Dillon D, et al. Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 2000;110:374-381
  12. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001;33:832-840
  13. Bertucci F, Bernard K, Loriod B, et al. Sensitivity issues in DNA array-based expression measurements and perfor- mance of nylon microarrays for small samples. Hum Mol Genet 1999;8:1715-1722
  14. Yoo HS. 21C Frontier Cancer Genome Project of Korea. J Korean Cancer Asso 2001;33(S):4
  15. Achary MP, Jaggernauth W, Gross E, Alfieri A, Klinger HP, Vikram B. Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different eDNA microarray patterns of gene expression. Cytogenet Cell Genet 2000;91:39-43
  16. Kitahara O, Katagiri T, Tsunoda T, Harima V, Nakamura V. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by eDNA microarray analysis. Neoplasia 2002:4(4):295-303
  17. Voganathan TN, Costello P, Chen X, et al. Integrin-linked kinase (ILK): a 'hot' therapeutic target. Biochem Pharmacol 2000;60(8):1115-1119
  18. White DE, Cardiff RD, Dedhar S, Muller WJ. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001;20(48):7064-7072
  19. SCandurro AB, Weldon CW, Figueroa VG, Alam J, Beckman BS. Gene microarray analysis reveals a novel hypoxia signal transduction pathway in human hepatocellular carcinoma cells. Int J Oncol 2001;19(1):129-135
  20. D'Amico M, Hulit J, Amanatullah DF, et al. The integrinlinked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways. J Bioi Chem 2000;275(42): 32649-32657
  21. Dedhar S, Williams B, Hannigan G. Integrin-linked kinase (ILK) : a regulator of integrin and growth-factor signaling. Trends Cell Bioi 1999;9(8):319-323
  22. Voganathan N, Vee A, Zhang Z, et al. Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties. Pharmacol Ther 2002;93(2-3):233
  23. Persad S, Attwell S, Gray V, et al. Inhibition of integrinlinked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTENmutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97(7):3207-3212
  24. Graff JR, Deddens JA, Konicek BW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res 2001;7(7):1987-1991
  25. Marotta A, Tan C, Gray V, et al. Dysregulation of integrin- linked kinase (ILK) signaling in colonic polyposis. Oncogene 2001;20(43):6250-6257
  26. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr Relat Cancer 2001;8(3):161-173
  27. Ostman A, Bohmer FD. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Bioi 2001;11(6):258-266
  28. Majercakova P. Role of protein phosphorylation in the development of tumors. Sb Lek 2000;101(3):215-228
  29. Chernoff J. Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J Cell Physiol 1999;180(2):173-181<173::AID-JCP5>3.0.CO;2-Y
  30. Fischer EH. Cell signaling by protein tyrosine phosphorylation. Adv Enzyme Regul 1999;39:359-369
  31. Bixby JL. Ligands and signaling through receptor-type tyrosine phosphatases. UBMB Life 2001;51(3):157-163
  32. Smits VA, Medema RH. Checking out the G(2)/M transition. Biochem Biophys Acta 2001;1519(1-2):1-12
  33. Arellano M, Moreno S. Regulation of CDK!cyciin complexes during the cell cycle. Int J Biochem Cell Bioi 1997;29(4):559573
  34. Gross I, Bassit B, Benezra M, Licht JD. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing\ ras activation. J Bioi Chem 2001 ;276(49):46460-46468
  35. Egan JE, Hall AB, Vatsula BA, Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci USA 2002;99(9):6041-6046
  36. Wong ES, Fong CW, Lim J, et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signaling. EMBO J 2002;21(18):4796-4808
  37. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284(5422):1994-1998
  38. Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simUltaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002;109(6):777-785